Insulin Degludec and Liraglutide

Novo Nordisk has expressed strong concerns that three of its best-selling GLP-1 drugs have been included in upcoming US price negotiations, warning this will slow down research and development efforts.

The FDA has officially removed Novo Nordisk's semaglutide products, Ozempic and Wegovy, from its drug shortage list after being listed since 2022, signaling improved supply availability.

The FDA has simultaneously approved two novel diabetes combination therapies: Novo Nordisk's Xultophy (insulin degludec/liraglutide) and Sanofi's Soliqua (insulin glargine/lixisenatide) for type 2 diabetes management.